School of Medicine
Showing 1-20 of 28 Results
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
Sean Mackey, M.D., Ph.D.
Redlich Professor, Professor of Anesthesiology, Perioperative, and Pain Medicine and, by courtesy, of Neurology
Current Research and Scholarly InterestsMultiple NIH funded projects to characterize CNS mechanisms of human pain. Comparative effectiveness of cognitive behavioral therapy and chronic pain self-management within the context of opioid reduction (PCORI funded). Single session pain catastrophizing treatment: comparative efficacy & mechanisms (NIH R01). Development and implementation of an open-source learning healthcare system, CHOIR (http://choir/stanford.edu), to optimize pain care and innovative research in real-world patients.
Professor (Research) of Microbiology and Immunology
Current Research and Scholarly InterestsI'm interested in immune monitoring of T cell responses to chronic pathogens and cancer, and the correlation of T cell response signatures with disease protection.
Ravi Majeti MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, RZ Cao Professor and Professor of Medicine (Hematology)
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
Assistant Professor of Pediatrics (Hematology/Oncology)
BioRobbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. After graduating with a BA from Columbia University, Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 (Mount/Majzner et al., Nature Medicine, 2018) B7-H3 (Majzner et al., Clinical Cancer Research, 2019), and ALK (Walker/Majzner et al., Molecular Therapy, 2017). Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al., Cancer Discovery, 2020). By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.
Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.
Associate Professor (Research) of Radiology (Cancer Early Detection-Canary Center)
Current Research and Scholarly InterestsThe Mallick Lab is focused on using integrative, multi-omic approaches to model the processes that govern cellular dynamics and to use those models to discover cancer biomarkers and molecular mechanisms.
Assistant Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
M. Peter Marinkovich, MD
Associate Professor of Dermatology
Current Research and Scholarly InterestsThe Marinkovich lab studies the function of epithelial extracellular matrix molecules, including integrins, collagens and laminins in epithelial development and carcinoma progression. We apply our discoveries in this area towards development of molecular therapies for carcinomas, hair disease and inherited epithelial adhesive disorders.
Johnson and Johnson Professor of Surgery
Current Research and Scholarly InterestsHost-Pathogen interactions; EBV B cell lymphomas; pathways of immune evasion in the growth and survival of EBV B cell lymphomas; mechanisms of graft rejection and tolerance induction; stem cell and solid organ transplantation.
Tarik F. Massoud, MD, PhD
Professor of Radiology (Neuroimaging and Neurointervention)
Current Research and Scholarly InterestsMy current interests are in molecular and translational imaging of the brain especially in neuro-oncology and cerebrovascular diseases, experimental aspects of neuroimaging, clinical neuroradiology, neuroradiological anatomy, and research education and academic training of radiologists and scientists.
Professor of Microbiology and Immunology, Emeritus
Current Research and Scholarly Interests1. Improvement of our newly discovered cancer prodrug regimen that permits noninvaisve visualization of drug activation. 2. Tracking tumors & cancer metastases using bacterial magnetite and newly developed single-cell tracking by MRI. 3. Molecular basis of bacterial planktonic and biofilm antibiotic resistance on Earth and under space microgravity -- development of new countermeasures; 4. Bioremediation.
Uchechukwu Megwalu, MD, MPH
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsOutcomes Research
Comparative Effectiveness Research
Head and Neck Cancer Epidemiology
SEER database analysis
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
Mrs. George A. Winzer Professor in Cell Biology
Current Research and Scholarly InterestsCELLULAR INFORMATION PROCESSING. We are using live single-cell microscopy approaches to understand the design principles of cell signaling circuits. Mammalian signaling processes have a unique logic due to the large number of signaling proteins, second messengers and chromatin modifiers involved in each decision process. We are particularly interested in understanding how cells make decisions to enter and exit the cell cycle and how they decide to polarize and move.
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
Leah S. Millheiser, MD, FACOG, NCMP
Clinical Professor, Obstetrics & Gynecology - General
Current Research and Scholarly InterestsResearch interest in the role of the central nervous system in female hypoactive sexual desire disorder.
Lloyd B. Minor, MD
Carl and Elizabeth Naumann Professorship for the Dean of the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurobiology and of Bioengineering
Current Research and Scholarly InterestsThrough neurophysiological investigations of eye movements and neuronal pathways, Dr. Minor has identified adaptive mechanisms responsible for compensation to vestibular injury in a model system for studies of motor learning. Following his discovery of superior canal dehiscence, he published a description of the disorder’s clinical manifestations and related its cause to an opening in the bone covering of the superior canal. He subsequently developed a surgical procedure to correct the problem.
Paul Salomon Mischel
Professor of Pathology and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research bridges cancer genetics, signal transduction and cellular metabolism as we aim to understand the molecular mechanisms that drive cancer development, progression, and drug resistance. We have made a series of discoveries that have identified a central role for ecDNA (extrachromosomal DNA) in cancer development, progression, accelerated tumor evolution and drug resistance.
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine and Professor, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.